Entry Point Capital, LLC Arcutis Biotherapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 17,774 shares of ARQT stock, worth $180,228. This represents 0.1% of its overall portfolio holdings.
Number of Shares
17,774
Previous 6,572
170.45%
Holding current value
$180,228
Previous $61.1 Million
99.73%
% of portfolio
0.1%
Previous 0.09%
Shares
2 transactions
Others Institutions Holding ARQT
# of Institutions
197Shares Held
129MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC11.7MShares$118 Million0.07% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$111 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$109 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$89.1 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$87.4 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $610M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...